Equillium to Present at 38th Annual Roth Conference

Equillium, a biotechnology innovator, announced its participation in the 38th Annual Roth Conference. Management will participate in a fireside chat on March 23, 2026, at 8:30am PT. Members of the management team will also be available for meetings with investors who are registered to attend the conference. Equillium is developing novel therapies to treat severe autoimmune and inflammatory disorders, with its lead candidate EQ504 targeting ulcerative colitis and inflammatory lung diseases.